Key Points
- Insider selling: CFO Kyle Piskel sold 2,145 shares at an average $18.46 on Feb 4, trimming his stake to 216,637 shares, and this follows larger insider disposals (including the CEO's ~125k‑share sale) that could pressure sentiment.
- Q4 beat but still unprofitable: Adaptive reported a $0.09 loss per share vs. a $0.19 consensus loss and revenue of $71.7M (up 51% YoY), yet margins remain negative and analysts still expect a full‑year loss.
- Mixed analyst backdrop: Several firms raised targets (JPMorgan to $21, BTIG to $22, Guggenheim to $21) and the consensus is a Moderate Buy with an average target of $17.56, while the stock recently traded down about 4.3% amid these developments.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) CFO Kyle Piskel sold 2,145 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $18.46, for a total transaction of $39,596.70. Following the sale, the chief financial officer owned 216,637 shares of the company's stock, valued at $3,999,119.02. The trade was a 0.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Kyle Piskel also recently made the following trade(s):
- On Monday, January 12th, Kyle Piskel sold 4,290 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $18.00, for a total transaction of $77,220.00.
- On Friday, November 28th, Kyle Piskel sold 162,820 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $19.50, for a total transaction of $3,174,990.00.
- On Monday, November 17th, Kyle Piskel sold 238 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.05, for a total transaction of $3,343.90.
Adaptive Biotechnologies Stock Down 4.3%
ADPT opened at $15.77 on Friday. The stock's fifty day moving average is $17.03 and its two-hundred day moving average is $15.20. The company has a market capitalization of $2.41 billion, a P/E ratio of -39.42 and a beta of 2.18. Adaptive Biotechnologies Corporation has a 52 week low of $6.26 and a 52 week high of $20.76.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 48.73% and a negative net margin of 21.48%.The business had revenue of $71.68 million during the quarter, compared to analysts' expectations of $59.38 million. During the same period in the prior year, the business earned ($0.23) EPS. The business's revenue for the quarter was up 51.0% compared to the same quarter last year. Equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.
Analysts Set New Price Targets
ADPT has been the subject of several recent research reports. Weiss Ratings restated a "sell (d-)" rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a research note on Saturday, January 31st. Guggenheim upped their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Monday, January 26th. BTIG Research lifted their price target on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a "buy" rating in a report on Friday. Finally, JPMorgan Chase & Co. upped their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an "overweight" rating in a research note on Friday. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $17.56.
Read Our Latest Research Report on ADPT
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC raised its stake in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock valued at $38,000 after buying an additional 1,565 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Adaptive Biotechnologies by 693.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 13,796 shares of the company's stock worth $224,000 after acquiring an additional 12,058 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Adaptive Biotechnologies by 9.9% in the 4th quarter. ProShare Advisors LLC now owns 34,057 shares of the company's stock valued at $553,000 after purchasing an additional 3,078 shares during the last quarter. Sigma Planning Corp boosted its stake in Adaptive Biotechnologies by 150.1% in the 4th quarter. Sigma Planning Corp now owns 32,550 shares of the company's stock worth $529,000 after purchasing an additional 19,535 shares in the last quarter. Finally, Jennison Associates LLC boosted its stake in Adaptive Biotechnologies by 103.9% in the 4th quarter. Jennison Associates LLC now owns 2,674,668 shares of the company's stock worth $43,437,000 after purchasing an additional 1,363,181 shares in the last quarter. 99.17% of the stock is currently owned by hedge funds and other institutional investors.
Key Adaptive Biotechnologies News
Here are the key news stories impacting Adaptive Biotechnologies this week:
- Positive Sentiment: Q4 results beat expectations — ADPT reported a $0.09 loss per share vs. a $0.19 consensus loss and revenue of $71.7M (up 51% YoY), which investors typically view as positive for growth outlook. Read More.
- Positive Sentiment: Analyst upgrade/target increase — JPMorgan raised its price target to $21 and maintained an overweight stance, implying meaningful upside versus recent levels and likely supporting buying interest. Read More.
- Neutral Sentiment: Multiple analyst write-ups and coverage: Zacks and other outlets published detail and comparisons to estimates; consensus remains a "Moderate Buy" with an average price target near the mid‑teens to low‑$20s — useful context but not a single catalyst. Read More.
- Neutral Sentiment: Full earnings materials and transcript are available for deeper review (management commentary and slide deck will guide whether revenue quality and guidance justify the rally). Read More.
- Negative Sentiment: Significant insider selling disclosed this week — CEO Chad M. Robins and other insiders sold large blocks (CEO ~125k shares; other insider sales also reported). Large insider sales can pressure sentiment even when results are strong. Read More.
- Negative Sentiment: Company remains unprofitable with negative margins and a negative ROE; analysts still expect a full-year loss (consensus EPS negative), which leaves valuation and timing of profitability as ongoing investor concerns. Read More.
- Neutral Sentiment: Reported short-interest data in this batch is effectively zero/unchanged and shows no immediate short‑squeeze dynamics; days‑to‑cover computed as 0.0, so short interest is not a current market driver. (Item flagged in recent data feeds.)
Adaptive Biotechnologies Company Profile
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
